Diabetologia

Diabetologia (diabetologia)

Journal positioning

Diabetologia is the flagship journal of the European Association for the Study of Diabetes (EASD), publishing diabetes-focused research across the full evidence spectrum — clinical and pragmatic trials, epidemiology and population science, and basic/translational science of islet biology, insulin action, complications, and metabolism. Unlike a broad endocrine journal, Diabetologia is diabetes-dedicated and explicitly welcomes rigorous basic and mechanistic science (beta-cell biology, insulin signaling, animal/cell models) alongside human clinical and epidemiologic work. Its defining expectation is a significant advance in understanding, preventing, treating, or explaining diabetes and its complications, not a small descriptive series or an association study with no mechanistic or clinical payoff. This skill is a fit / venue-selection / re-framing aid; it is not clinical or regulatory advice and does not replace the journal's current instructions for authors. Before submitting, re-check the live Diabetologia author instructions.

When to trigger

• The author names Diabetologia for a diabetes clinical, epidemiological, or basic/translational study and wants a fit/framing check.
• A diabetes study must be re-framed around a mechanism, a prevention/treatment question, or a complications-outcome question.
• The author is choosing between Diabetologia (diabetes-specific, incl. basic science), JCEM (broad endocrine), and The Lancet Diabetes & Endocrinology (high-impact trials).
• The author needs the journal's reporting-guideline, registration, and basic/animal-study expectations for diabetes research.

Scope & topic fit

• Type 1 and type 2 diabetes: pathogenesis, prevention, glucose-lowering therapy, and management trials.
• Diabetes epidemiology and population science: incidence, risk factors, and outcomes across cohorts.
• Islet and beta-cell biology, insulin secretion and action, and metabolic mechanism in cells and animal models.
• Diabetic complications: nephropathy, retinopathy, neuropathy, and cardiovascular disease in diabetes, with mechanism or outcome rigor.
• Gestational diabetes, monogenic diabetes, and metabolic phenotyping studies.
• Diabetes biomarkers, genetics/genomics, and -omics with disease relevance and validation.

Method & evidence bar

• Clinical studies must be adequately powered with prespecified, patient-centered diabetes endpoints; trials require prospective registration and the registration number.
• The applicable reporting guideline and checklist are expected: CONSORT for trials, STROBE for observational/epidemiologic work, PRISMA for systematic reviews, ARRIVE for animal studies.
• Basic/translational work needs rigorous controls, biological replication, validated reagents/models, and blinded/randomized animal experiments where applicable.
• Mechanistic claims require perturbation evidence and, where feasible, anchoring to human islets, tissue, or cohorts; glucose/insulin-clamp and metabolic methods must be described.
• Epidemiologic claims must address confounding, bias, and generalizability; causal language must match the design.
• Effect estimates need confidence intervals and absolute as well as relative measures.

Structure & house style

• EASD/Springer format with a structured abstract (aims/hypothesis, methods, results, conclusions) and a research-in-context/significance statement; re-check current article types and limits on the live guide.
• The introduction frames the diabetes-biology or clinical gap; the discussion states the mechanistic or practice implication and bounds overreach.
• A CONSORT/STROBE/PRISMA flow diagram is expected for the relevant clinical design; animal work reports ARRIVE-aligned detail.
• Figures show representative data with statistics, N, and replication; an electronic supplement carries full methods, the protocol/SAP, and additional experiments.